SCHEMBL3079933

SCHEMBL3079933

Cc1cc(-c2nc(-c3ccc(C(O)CNS(C)(=O)=O)cc3)no2)nc(NC(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.39
S1PR3 Q99500 3/20 0.35
ADRB2 P07550 3/20 0.34
ADRB1 P08588 3/20 0.34
ADRB3 P13945 3/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GLA P06280 1/20 0.34
BLM P54132 1/20 0.34
POLB P06746 1/20 0.34
IDH1 O75874 1/20 0.34
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084750 0.90 S1PR1 (0.37) S1PR1S1PR3MEN1KMT2APOLB
SCHEMBL3092128 0.86 S1PR1 (0.36) S1PR1S1PR3POLBIDH1TP53
SCHEMBL3087824 0.85 S1PR1 (0.44) S1PR1S1PR3POLBIDH1NPC1
SCHEMBL3093051 0.85 S1PR1 (0.43) S1PR1S1PR3POLBIDH1NPC1
SCHEMBL3097774 0.84 S1PR1 (0.45) S1PR1S1PR3
SCHEMBL3079543 0.84 S1PR1 (0.41) S1PR1S1PR3ADRB2ADRB1ADRB3
SCHEMBL3085995 0.84 S1PR1 (0.38) S1PR1S1PR3IDH1ALDH1A1TP53
SCHEMBL3795966 0.79 S1PR1 (0.37) S1PR1POLBIDH1NPC1ALDH1A1
SCHEMBL27828595 0.77 MAPT (0.48) S1PR1S1PR3LMNAKDM4EPOLB
SCHEMBL3276539 0.76 S1PR1 (0.47) S1PR1S1PR3ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD S1PR1 989/4885S1PR3 943/4885ADRB2 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.